



Technical Report No. 57-2

Analytical Method Development and Qualification for Biotechnology Products

PDA Analytical Method Development and Qualification of Biotechnology Products Technical Report Team

Authors

Melissa J. Smith, MJ Quality Solutions, (Chair)

Florence Baudoux, GlaxoSmithKline Biologicals

Marta Germano, Janssen Pharmaceutical Companies of Johnson & Johnson

Joachim Leube, Ph.D., Crucell

Sheila Magil, Ph.D., BioProcess Technology Consultants, Inc.

Carl Gustav-Millinger, Quality & Qualimetrics Consultancy QQC AB

Dwayne Neal, Emergent BioSolutions

Phillip Ramsey, Emergent BioSolutions

Michael Rooney, Ph.D., Jazz Pharmaceuticals

Rebecca Sendak, Ph.D., Sanofi

Zoran Sosic, Biogen Idec

Earl K. Zablackis, Ph.D., Sanofi Pasteur

Contributors

Raphael Bar, Ph.D., BR Consulting

DaoTian Fu, Ph.D., Livzon Mabpharm, Inc.

Kenji Furuya, Boehringer Ingelheim

Stephan O. Krause, Ph.D., MedImmune

Nadine M. Ritter, Global Biotech Experts, LLC

Jane Weitzel, Quality Analysis Consultants

DISCLAIMER: The content and views expressed in this technical report are the result of a consensus achieved by the authorizing task force and are not necessarily the views of the organizations they represent.

Analytical Method Development and Qualification for Biotechnology Products

Technical Report No. 57-2

ISBN: 978-0-939459-74-2

© 2015 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	4.2.5 Readiness to Proceed	30
1.1 Method Lifecycle	2	4.3 Method Qualification Plan or Protocols.....	30
1.2 Purpose and Scope.....	2	4.3.1 Qualification Approach	30
2.0 GLOSSARY OF TERMS	4	4.3.2 Qualification Characteristics	31
2.1 Abbreviations	6	4.3.2.1 Reference Standards	31
3.0 METHOD DEVELOPMENT	7	4.3.2.2 Specificity	31
3.1 Method Definition.....	7	4.3.2.3 Spiked Samples.....	32
3.1.1 Analytical Target Profile	9	4.3.2.4 Linearity and Range.....	32
3.2 Method Selection	11	4.3.2.5 Accuracy	32
3.2.1 Risk Assessment.....	12	4.3.2.6 Repeatability and Intermediate	
3.2.2 Selection of Platform-Based Technologies ..	12	Precision.....	32
3.2.3 Conclusion of the Selection Process.....	13	4.3.2.7 Detection Limits and Quantitation	
3.3 Method Development and Optimization.....	13	Limits	34
3.3.1 Phased Approach	13	4.3.2.8 Robustness.....	34
3.3.2 Risk Considerations	13	4.3.2.9 Stability-Indicating Assessment	34
3.3.3 Design of Experiment.....	14	4.4 Execution	35
3.3.3.1 List and Description of Experiments ...	15	4.5 Qualification Evaluation	35
3.3.4 Execution of Development Activities	16	4.5.1 Specificity.....	35
3.3.4.1 Samples and Standards.....	16	4.5.2 Accuracy, Precision, Linearity, and Range... 35	
3.3.4.2 Known or Expected Impurities.....	17	4.5.3 Detection Limits and Quantitation Limits .	36
3.3.4.3 Forced-Degradation Samples.....	18	4.5.4 Statistical Assessments and Practical vs.	
3.3.4.4 Equipment	18	Statistical Differences.....	36
3.3.4.5 System Suitability	18	4.5.5 Qualification Excursions.....	36
3.3.4.6 Robustness.....	19	4.6 Method Qualification Report.....	37
3.3.5 Evaluation of Development Activities	20	4.6.1 Standard Operating Procedure.....	37
3.4 Method Deliverables.....	20	4.6.2 Supportive Procedures	37
3.4.1 Baseline and Best-Practice Deliverables..	21	4.6.3 Data.....	38
3.4.2 Documentation Deliverables	23	4.6.4 System Suitability and Sample	
3.4.3 Physical Deliverables.....	24	Validity Criteria	38
4.0 METHOD QUALIFICATION	26	4.7 Conclusions and Deliverables	38
4.1 Overview	26	5.0 ANALYTICAL METHOD COMPARABILITY AND	
4.2 Method Development Package Assessment ..	29	ANALYTICAL METHOD TRANSFER	45
4.2.1 Intended Use and Performance.....	29	6.0 METHOD LIFECYCLE MANAGEMENT	
4.2.2 Standard Operating Procedure	29	CONTINUUM	46
4.2.3 Physical Deliverables: Material and		7.0 CONCLUSION	48
Equipment	30	8.0 REFERENCES	49
4.2.4 Robustness.....	30		

FIGURES AND TABLES INDEX

Figure 1.1-1	Method Lifecycle and its Links to Product Development	2	Table 3.4.1-1	Baseline and Best Practices for Deliverables of a Developed Method ..	22
Figure 1.2-1	Table of Contents Map.....	3	Figure 3.4.2.1-1	Documentation Deliverables	24
Figure 3.0-1	Method Development Process.....	7	Figure 3.4.3-1	Physical Materials Deliverables	25
Table 3.1-1	Overview of Method Definition Process...	8	Figure 4.1-1	Models of Qualification.....	27
Table 3.1-2	Points to Consider for Method Definition...	9	Table 4.3.2.6-1	Sample IP Matrix.....	33
Table 3.2-1	Inputs and Outputs of Method Selection Process.....	11	Figure 4.3.2.6-1	Sample Nested Design for IP for Day 1.....	33
Figure 3.3.2-1	Risk Assessment Process Map	14	Table 4.3.2.6-2	Sample Restricted Maximum Likelihood Variance Component Estimates for IP Matrix.....	34
Figure 3.3.3.1-1	Iterative Method Development Process	15	Table 4.7-1	Evaluations and Deliverables for AMD and AMQ.....	39
Table 3.3.4.6-1	Fractional Factorial Design: Factors, Levels with Result from Each Run, and Factor Effect p-values	19	Figure 6.0-1	Development and Qualification Lifecycle Deliverables	46
Figure 3.3.4.6-1	Normal Plot Robustness Factor Assessment	20			